Dr. Reddy’s Sets July 22 Board Meet, Imposes Trading Blackout for Q1 FY27 Results
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.
Dr. Reddy’s Laboratories has notified exchanges that its board will meet on July 22, 2026, to consider the company’s unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The move underscores the company’s regular financial reporting cycle to investors in India and on the NYSE.
The company also announced that its trading window for dealing in its securities will be closed from June 24, 2026, to July 24, 2026, in line with SEBI’s insider trading rules. This blackout period is designed to prevent trading by insiders while quarterly results are being prepared, aiming to protect market integrity and reassure shareholders on governance practices.
The most recent analyst rating on (RDY) stock is a Buy
with a $1540.00 price target.
To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock,
see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock,
click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based pharmaceutical company focused on generic and branded medicines for global markets. Listed in India and on the New York Stock Exchange, it operates across formulations and active pharmaceutical ingredients, targeting regulated markets such as the U.S. and Europe as well as emerging economies.
Average Trading Volume: 2,355,214
Technical Sentiment Signal: Buy
Current Market Cap: $11.25B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.
